CASPR2 antibodies (20%) and GAD65 antibodies (31%) were between those values, again consistent with the literature reporting on 20–24% [32, 48] and 33–62% [17, 35] of cases, respectively, having hippocampal lesions or atrophy/sclerosis. This evidence concerns the gene GAD2 and Atrophy.